Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
mű, amelyben megjelent: European Journal of Cancer
date of publication: 2017-06-04
main subject: hepatocellular carcinoma
Cites articles
There is nothing here
Article - wd:Q38737964